Marketed under the brand name Zepbound for weight loss, tirzepatide is also approved as Mounjaro for type 2 diabetes management
Global obesity spending reached nearly $24bn in 2023, an over sevenfold growth in value in just three years, driven by the advent of new agents, and from 2024 onwards the market is forecasted to accelerate rapidly, with a possible 24-27% CAGR to 2028, and a potential value of up to $131bn by 2028, according to the IQVIA Institutes Global Use of Medicines 2024 report 4
If so, how are they covered
Weekly self-injections ensure you stay on track without frequent visits to the clinic
Resolving controversies on the path to Alzheimers therapeutics
Semaglutide acts primarily through the gut-pancreas-brain axis, driving substantial weight loss and systemic metabolic improvements, with secondary yet potent hepatic benefits